Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00921752
First received: June 12, 2009
Last updated: December 3, 2009
Last verified: December 2009
  Purpose

To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.


Condition
Cardiovascular Risk

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Percent rate of patients achieving target LDL cholesterol goals [ Time Frame: On each of the 3 visits performed during the study ] [ Designated as safety issue: No ]
  • Percent rate of patients achieving 50% or more reduction in LDL-cholesterol [ Time Frame: On each of the 3 visits performed during the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent rate of patients achieving target secondary (total Ch, triglycerides, HDL Ch) goals [ Time Frame: On each of the 3 visits performed during the study ] [ Designated as safety issue: No ]
  • Percent rate of compliance among patients in the study [ Time Frame: On each of the 3 visits performed during the study ] [ Designated as safety issue: No ]

Estimated Enrollment: 1500
Study Start Date: May 2009
Study Completion Date: November 2009
Groups/Cohorts
Patients at high cardiovascular risk

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Ambulatory clinics

Criteria

Inclusion Criteria:

  • Patients at high cardiovascular risk according to Framingham or SCORE rates

Exclusion Criteria:

  • Not eligible for lipid or statin therapy
  • Intolerance to therapy
  • Patients at low or intermediate CV risk
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00921752

Locations
Hungary
Research Site
Baja, Hungary
Research Site
Bekescsaba, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest Iii District, Hungary
Research Site
Cegled, Hungary
Research Site
Debrecen, Hungary
Research Site
Gyongyos, Hungary
Research Site
Gyula, Hungary
Research Site
Jaszbereny, Hungary
Research Site
Kalocsa, Hungary
Research Site
Karcag, Hungary
Research Site
Kecskemet, Hungary
Research Site
Kisvarda, Hungary
Research Site
Mohacs, Hungary
Research Site
Nyiregyhaza, Hungary
Research Site
Oroshaza, Hungary
Research Site
Paszto, Hungary
Research Site
Puspokladany, Hungary
Research Site
Salgotarjan, Hungary
Research Site
Szarvas, Hungary
Research Site
Szecseny, Hungary
Research Site
Szekesfehervar, Hungary
Research Site
Szekszard, Hungary
Research Site
Szolnok, Hungary
Research Site
Tatabanya, Hungary
Research Site
Vac, Hungary
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Mark Laszlo, MD, PHD County Hospital Bekes, Gyula
Study Director: Csaba Csongvai, MD AstraZeneca Hungary
Study Chair: Eva Gulyas AstraZeneca Hungary
  More Information

Publications:

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00921752     History of Changes
Other Study ID Numbers: NIS-CHU-DUM-2009/1
Study First Received: June 12, 2009
Last Updated: December 3, 2009
Health Authority: Hungary: National Institute of Pharmacy

Keywords provided by AstraZeneca:
Lipid therapy
high CV risk
lipid goal attainment
High cardiovascular risk patients

ClinicalTrials.gov processed this record on November 25, 2014